UP!
| 2015-10-21 | Downgrade | JMP Securities | Market Perform | |
| 2015-10-21 | Downgrade | Cowen and Company | Outperform to Hold | |
| 2015-10-21 | Downgrade | FBR & Co. | Outperform to Market Perform | $2.00 |
| 2015-10-21 | Downgrade | Roth Capital | Buy to Neutral | $13.00 to $1.00 |
| 2015-10-21 | Downgrade | FBR & Co | Outperform to Market Perform | $2.00 |
| 2015-10-16 | Reiterated Rating | Roth Capital | Buy | $13.00 |
| 2015-08-10 | Reiterated Rating | MLV & Co. | Buy | $6.50 |
| 2015-06-08 | Reiterated Rating | Roth Capital | Buy | $13.00 |
| 2015-06-02 | Reiterated Rating | Cowen and Company | Buy | |
| 2015-04-27 | Lower Price Target | Roth Capital | Buy | $20.00 to $13.00 |
| 2015-04-21 | Initiated Coverage | FBR & Co. | Outperform | $6.00 |
| 2015-04-10 | Initiated Coverage | Cowen and Company | Outperform | |
| 2015-04-10 | Initiated Coverage | Canaccord Genuity | Outperform | |
| 2015-03-13 | Set Price Target | MLV & Co. | Buy | $6.50 |
| 2015-02-06 | Lower Price Target | Roth Capital | Buy | $27.00 to $20.00 |
| 2014-11-06 | Reiterated Rating | Roth Capital | Positive | |
| 2014-10-29 | Reiterated Rating | Roth Capital | Buy | |
| 2014-08-07 | Reiterated Rating | JMP Securities | Market Outperform | $10.00 to $9.00 |
| 2014-05-09 | Boost Price Target | MLV & Co. | Buy | $6.00 to $6.50 |
| 2014-03-13 | Reiterated | MLV & Co | Buy | $10 to $6 |
| 2014-03-13 | Lower Price Target | MLV & Co. | Buy | $10.00 to $6.00 |
| 2014-03-12 | Downgrade | Stifel | Hold to Sell | |
| 2014-03-12 | Lower Price Target | JMP Securities | $14.00 to $10.00 | |
| 2014-03-12 | Downgrade | BMO Capital Markets | Market Perform to Underperform | $5.00 to $1.00 |
| 2014-03-12 | Downgrade | Stifel Nicolaus | Hold to Sell | |
| 2013-11-05 | Reiterated | MLV & Co | Buy | $16 to $10 |
| 2013-11-05 | Lower Price Target | Jefferies Group | Buy | $20.00 to $19.00 |
| 2013-11-05 | Lower Price Target | BMO Capital Markets | $9.00 to $5.00 | |
| 2013-11-05 | Lower Price Target | MLV & Co. | Buy | $16.00 to $10.00 |
| 2013-10-28 | Boost Price Target | JMP Securities | Market Outperform | $11.00 to $14.00 |
| 2013-10-28 | Reiterated Rating | Jefferies Group | Positive | $22.00 to $20.00 |
| 2013-06-06 | Reiterated | MLV & Co | Buy | $18.50 to $16 |
| 2013-04-01 | Reiterated | MLV & Co | Buy | $16 to $18.50 |
| 2012-08-30 | Initiated | Stifel Nicolaus | Hold | |
| 2012-01-05 | Initiated | Rodman & Renshaw | Mkt Outperform | $8 |
| 2012-01-05 | Initiated | |||
| 2011-03-14 | Reiterated | Barclays Capital | Equal Weight | $2 to $4 |
| 2011-02-28 | Upgrade | Canaccord Genuity | Hold to Buy | $4.50 to $8 |
| 2010-11-09 | Initiated | MLV Capital | Buy | $8.50 |
| 2010-08-26 | Initiated | Morgan Joseph | Buy | $6 |
| 2010-05-10 | Upgrade | Roth Capital | Hold to Buy | $4 |
| 2010-02-19 | Initiated | RBC Capital Mkts | Sector Perform | $5 |
| 2010-02-17 | Downgrade | Roth Capital | Buy to Hold | $4 |
| 2009-11-05 | Upgrade | Roth Capital | Hold to Buy | $2 to $4 |
| 2009-02-27 | Downgrade | Wachovia | Mkt Perform to Underperform | |
| 2009-02-27 | Downgrade | Roth Capital | Buy to Hold | $11 to $2 |
| 2009-02-27 | Downgrade | Rodman & Renshaw | Mkt Outperform to Mkt Perform | |
| 2009-02-27 | Downgrade | RBC Capital Mkts | Outperform to Sector Perform | |
| 2009-02-27 | Downgrade | Lazard Capital | Buy to Hold | |
| 2008-12-01 | Initiated | Banc of America Sec | Neutral | |
| 2008-11-20 | Reiterated | Rodman & Renshaw | Mkt Outperform |
| 2015-10-21 | Downgrade | JMP Securities | Market Perform | |
| 2015-10-21 | Downgrade | Cowen and Company | Outperform to Hold | |
| 2015-10-21 | Downgrade | FBR & Co. | Outperform to Market Perform | $2.00 |
| 2015-10-21 | Downgrade | Roth Capital | Buy to Neutral | $13.00 to $1.00 |
| 2015-10-21 | Downgrade | FBR & Co | Outperform to Market Perform | $2.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In SNTA 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Bahcall Safi R President and CEO | 1.97% (2053135) | SNTA / |
| Gollust Keith R | 1.47% (1539169) | SNTA / |
| WILSON ROBERT N | 0.73% (760936) | HES / SCHW / SNTA / VVUS / |
| Taub Rebecca Chief Medical Officer, EVP R&D | 0.70% (729066) | SNTA / |
| Whitaker Anne Clem President and CEO | 0.48% (500000) | CREE / SNTA / VRX / |
| Kovner Bruce | 0.33% (340970) | CPXX / SNTA / |
| CRAVES FRED B | 0.28% (296067) | DERM / SNTA / |
| Ramachandra Sumant President, R&D | 0.07% (75000) | HSP / SNTA / |
| REARDON WILLIAM S | 0.05% (49392) | HQH / HQL / IDRA / SNTA / |
| Schneebaum Marc R SVP and CFO | 0.04% (42277) | GNVC / SNTA / |
| Schor Chen Executive VP and COO | 0.04% (37178) | SNTA / TORC / |
| Vukovic Vojo SVP, Chief Medical Officer | 0.03% (35249) | SNTA / |
| KUFE DONALD W | 0.02% (25748) | SNTA / |
| Bernitz Steven B SVP, Corporate Development | 0.02% (25000) | SNTA / |
| Singh Amar Sr. VP, Business & Comm. Dvp. | 0.02% (21031) | SNTA / |
| Morenstein Scott D | 0.02% (17857) | CPXX / SNTA / THLD / |
| Rieder Wendy E VP, IP and Legal, Gen. Counsel | 0.02% (17730) | SNTA / |
| Ehrlich Keith S VP, Fin. and Admin., CFO | 0.02% (17573) | AVEO / SNTA / |
| Koya Keizo Sr. VP, Drug Development | 0.01% (12999) | SNTA / |
| Levy Richard S | 0.01% (9100) | INCY / SNTA / |
UM